Compare Stocks: CTMX, PHVS, SLS, and NKTR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.70 -1.8%	$3.28	$2.66 ▼ $8.21	$588.33M	2.14	4.28 million shs	3.03 million shs
NKTR Nektar Therapeutics	$57.06 -3.9%	$70.99	$33.40 ▼ $109.00	$1.95B	1.14	1.12 million shs	2.56 million shs
PHVS Pharvaris	$32.02 -2.9%	$35.29	$20.65 ▼ $43.25	$2.09B	-2.33	1.06 million shs	597,650 shs
SLS SELLAS Life Sciences Group	$11.61 -3.1%	$12.41	$1.39 ▼ $15.88	$2.34B	2.52	6.57 million shs	4.44 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-2.17%	-21.05%	-20.24%	+12.03%
NKTR Nektar Therapeutics	0.00%	-14.96%	-23.46%	-10.35%	-5.42%
PHVS Pharvaris	0.00%	-11.96%	-13.46%	-5.85%	+31.12%
SLS SELLAS Life Sciences Group	0.00%	+1.04%	-23.67%	-6.30%	+612.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.70 -1.8%	$3.28	$2.66 ▼ $8.21	$588.33M	2.14	4.28 million shs	3.03 million shs
NKTR Nektar Therapeutics	$57.06 -3.9%	$70.99	$33.40 ▼ $109.00	$1.95B	1.14	1.12 million shs	2.56 million shs
PHVS Pharvaris	$32.02 -2.9%	$35.29	$20.65 ▼ $43.25	$2.09B	-2.33	1.06 million shs	597,650 shs
SLS SELLAS Life Sciences Group	$11.61 -3.1%	$12.41	$1.39 ▼ $15.88	$2.34B	2.52	6.57 million shs	4.44 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	0.00%	-2.17%	-21.05%	-20.24%	+12.03%
NKTR Nektar Therapeutics	0.00%	-14.96%	-23.46%	-10.35%	-5.42%
PHVS Pharvaris	0.00%	-11.96%	-13.46%	-5.85%	+31.12%
SLS SELLAS Life Sciences Group	0.00%	+1.04%	-23.67%	-6.30%	+612.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	340.74% Upside
NKTR Nektar Therapeutics	2.77	Moderate Buy	$138.50	142.73% Upside
PHVS Pharvaris	2.80	Moderate Buy	$59.87	86.97% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-13.87% Downside

Current Analyst Ratings Breakdown

Latest CTMX, PHVS, SLS, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/23/2026	NKTR Nektar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $50.00
9/16/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/14/2026	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$65.00
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/10/2026	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $44.00
9/9/2026	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$42.00 ➝ $50.00
9/9/2026	PHVS Pharvaris	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$50.00 ➝ $65.00
9/9/2026	PHVS Pharvaris	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
9/9/2026	PHVS Pharvaris	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $62.00
9/9/2026	PHVS Pharvaris	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$79.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$76.20M	7.72	N/A	N/A	$0.58 per share	4.66
NKTR Nektar Therapeutics	$55.23M	35.27	N/A	N/A	$4.41 per share	12.94
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest CTMX, PHVS, SLS, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
NKTR Nektar Therapeutics	N/A	10.42	10.42
PHVS Pharvaris	N/A	11.94	11.94
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
NKTR Nektar Therapeutics	75.88%
PHVS Pharvaris	N/A
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
NKTR Nektar Therapeutics	2.50%
PHVS Pharvaris	11.84%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
PHVS Pharvaris	148	65.41 million	57.66 million	Not Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Not Optionable

CTMX, PHVS, SLS, and NKTR Headlines

Recent News About These Companies

SELLAS Life Sciences präsentiert auf der AACR-Konferenz 2026 zu Bauchspeicheldrüsenkrebs präklinische Daten zur Wirksamkeit von SLS009 in Pankreaskrebsmodellen

September 26 at 1:39 AM | de.marketscreener.comD

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

September 25 at 1:00 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 24 at 5:34 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 22, 2026 | globenewswire.com

SELLAS Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

September 21, 2026 | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Should You Sell?

September 17, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 17, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 15, 2026 | globenewswire.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 4.8% - Here's Why

September 11, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 10, 2026 | prnewswire.com

Wellington Management Group LLP Grows Stock Holdings in SELLAS Life Sciences Group, Inc. $SLS

September 9, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 8, 2026 | globenewswire.com

SELLAS Life Sciences Group, Inc. (SLS)

September 4, 2026 | finance.yahoo.com

Bank of New York Mellon Corp Makes New Investment in SELLAS Life Sciences Group, Inc. $SLS

September 4, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 3, 2026 | prnewswire.com

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

September 3, 2026 | finance.yahoo.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of August

September 2, 2026 | seekingalpha.com

Sellas gears up to present preclinical SLS009 data for pancreatic cancer at major oncology conference

September 2, 2026 | msn.com

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

September 2, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 1, 2026 | globenewswire.com

Why analysts think Sellas Life Sciences stock can gain 150% from here

September 1, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTMX, PHVS, SLS, and NKTR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.70 -0.05 (-1.82%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.70 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Nektar Therapeutics NASDAQ:NKTR

$57.06 -2.32 (-3.91%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$57.53 +0.47 (+0.82%)

As of 09/25/2026 07:30 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Pharvaris NASDAQ:PHVS

$32.02 -0.97 (-2.94%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$32.63 +0.61 (+1.90%)

As of 09/25/2026 07:58 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

SELLAS Life Sciences Group NASDAQ:SLS

$11.61 -0.37 (-3.09%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$11.55 -0.06 (-0.52%)

As of 09/25/2026 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, PHVS, SLS, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, PHVS, SLS, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, PHVS, SLS, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTMX, PHVS, SLS, and NKTR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Nektar Therapeutics NASDAQ:NKTR

Pharvaris NASDAQ:PHVS

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, PHVS, SLS, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, PHVS, SLS, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, PHVS, SLS, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTMX, PHVS, SLS, and NKTR Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Nektar Therapeutics NASDAQ:NKTR

Pharvaris NASDAQ:PHVS

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools